Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk A Prespecified Secondary Analysis of a Randomized Clinical Trial /

Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Landi Antonio
Alasnag Mirvat
Heg Dik
Frigoli Enrico
Malik Fazila Tun Nesa
Gomez-Blazquez Ivan
Pourbaix Suzanne
Chieffo Alaide
Spaulding Christian
Sainz Fermin
Routledge Helen
Andò Giuseppe
Testa Luca
Sciahbasi Alessandro
Contractor Hussain
Jepson Nigel
Mieres Juan
Imran Syed Saqib
Noor Husam
Smits Pieter C
Valgimigli Marco
Kollaborációs szervezet: MASTER DAPT Investigators
Merkely Béla
Ungi Imre
Format: Article
Published: 2024
Series:JAMA CARDIOLOGY 9 No. 1
Subjects:
doi:10.1001/jamacardio.2023.4316

mtmt:34573779
Online Access:http://publicatio.bibl.u-szeged.hu/29531
LEADER 04214nab a2200493 i 4500
001 publ29531
005 20240213103830.0
008 240213s2024 hu o 000 eng d
022 |a 2380-6583 
024 7 |a 10.1001/jamacardio.2023.4316  |2 doi 
024 7 |a 34573779  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a eng 
100 1 |a Landi Antonio 
245 1 0 |a Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk   |h [elektronikus dokumentum] :  |b A Prespecified Secondary Analysis of a Randomized Clinical Trial /  |c  Landi Antonio 
260 |c 2024 
300 |a 35-44 
490 0 |a JAMA CARDIOLOGY  |v 9 No. 1 
520 3 |a Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR.This prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019. A total of 4579 patients with HBR were randomized at 1 month after PCI to abbreviated or standard DAPT. Data were analyzed from July 1 to October 31, 2022.Abbreviated (immediate DAPT discontinuation, followed by single APT for ≥6 months) or standard (DAPT for ≥2 additional months, followed by single APT for 11 months) treatment groups.One-year net adverse clinical events (NACEs) (a composite of death due to any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (MACCEs) (a composite of death due to any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding (MCB).Of the 4579 patients included in the analysis, 1408 (30.7%) were women and 3171 (69.3%) were men (mean [SD] age, 76.0 [8.7] years). Ischemic and bleeding events were similar between sexes. Abbreviated DAPT was associated with comparable NACE rates in men (hazard ratio [HR], 0.97 [95% CI, 0.75-1.24]) and women (HR, 0.87 [95% CI, 0.60-1.26]; P = .65 for interaction). There was evidence of heterogeneity of treatment effect by sex for MACCEs, with a trend toward benefit in women (HR, 0.68 [95% CI, 0.44-1.05]) but not in men (HR, 1.17 [95% CI, 0.88-1.55]; P = .04 for interaction). There was no significant interaction for MCB across sex, although the benefit with abbreviated DAPT was relatively greater in men (HR, 0.65 [95% CI, 0.50-0.84]) than in women (HR, 0.77 [95% CI, 0.53-1.12]; P = .46 for interaction). Results remained consistent in patients with acute coronary syndrome and/or complex PCI.These findings suggest that women with HBR did not experience higher rates of ischemic or bleeding events compared with men and may derive particular benefit from abbreviated compared with standard DAPT owing to these numerically lower rates of events.ClinicalTrials.gov Identifier: NCT03023020. 
650 4 |a Klinikai orvostan 
700 0 1 |a Alasnag Mirvat  |e aut 
700 0 1 |a Heg Dik  |e aut 
700 0 1 |a Frigoli Enrico  |e aut 
700 0 1 |a Malik Fazila Tun Nesa  |e aut 
700 0 2 |a Gomez-Blazquez Ivan  |e aut 
700 0 2 |a Pourbaix Suzanne  |e aut 
700 0 2 |a Chieffo Alaide  |e aut 
700 0 2 |a Spaulding Christian  |e aut 
700 0 2 |a Sainz Fermin  |e aut 
700 0 2 |a Routledge Helen  |e aut 
700 0 2 |a Andò Giuseppe  |e aut 
700 0 2 |a Testa Luca  |e aut 
700 0 2 |a Sciahbasi Alessandro  |e aut 
700 0 2 |a Contractor Hussain  |e aut 
700 0 2 |a Jepson Nigel  |e aut 
700 0 2 |a Mieres Juan  |e aut 
700 0 2 |a Imran Syed Saqib  |e aut 
700 0 2 |a Noor Husam  |e aut 
700 0 2 |a Smits Pieter C  |e aut 
700 0 2 |a Valgimigli Marco  |e aut 
700 0 2 |a Kollaborációs szervezet: MASTER DAPT Investigators  |e aut 
700 0 2 |a Merkely Béla  |e aut 
700 0 2 |a Ungi Imre  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/29531/1/Landi.pdf  |z Dokumentum-elérés